NanoVibronix, Inc. (NAOV)

0.7210 -0.0300 (-3.99%) 收市：04:00PM EDT

NanoVibronix, Inc.

969 Pruitt Avenue
Tyler, TX 77569
United States
(914) 233-3004
https://www.nanovibronix.com

版塊: Healthcare
行業: Medical Devices
全職員工: 10

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Brian M. Murphy	CEO & Director	382.5k	無	1957
Mr. Stephen R. Brown CPA	Chief Financial Officer	292.5k	無	1956
Dr. Harold Jacob M.D.	Chief Medical Officer & Director	無	無	1954
Mr. Amir Rippel	Vice President of Marketing	無	無	無
Ms. Lindsey Harrison	Vice President of Sales	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the non-invasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy in the United States, Israel, Europe, Australia, India, and internationally. The company's product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. It also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation. It sells its products directly to patients, as well as through distributor agreements. The company was incorporated in 2003 and is headquartered in Tyler, Texas.

公司管治

截至 無 止，NanoVibronix, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。